Latest news with #RiadMishlawi
Mid East Info
24-04-2025
- Business
- Mid East Info
Hikma reiterates full year guidance following good start to the year - Middle East Business News and Information
Amman, Jordan: Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading ahead of its Annual General Meeting. Riad Mishlawi, Hikma's CEO, said: 'We are pleased to reiterate our Group guidance for 2025. As a global company with strong local expertise and footprint, we are leveraging our manufacturing proficiency and advanced technologies to meet the needs of our customers and patients across our markets. Looking ahead, and recognising the broader geo-political challenges, we are well-positioned. Our step up in R&D investment, alongside local manufacturing enhancements, and strategic partnerships will continue to strengthen our portfolio and pipeline and ensure sustained success.' Injectables Our global Injectables business is delivering a solid revenue performance, driven by each of our three geographies. We are seeing strong demand for our products across our European and MENA markets, where we continue to launch new products. In North America we are benefitting from good demand for the recently launched liraglutide injection and the contribution from the newly acquired Xellia portfolio. This is helping to offset increased competition across some of our existing higher margin products. We expect momentum to improve in the second half driven by new product launches and contract manufacturing. We are making excellent progress in the enhancements to our Bedford, Ohio facility, which will significantly increase our US-based injectables manufacturing capacity. We continue to expect 2025 Injectables revenue to grow in the range of 7% to 9%. Phasing and mix of sales will impact margins in the first half but we continue to expect full year core operating margin to be in the mid-30s. Branded Our Branded business is performing well. We continue to make good progress in building our diversified portfolio of products used to treat chronic illnesses, with a focus on oncology and lifestyle diseases, supported by our global expertise and strong local market position. Our leading presence in the MENA region, combined with the breadth of our reach and strong commercial capabilities positions us as a partner of choice. We recently signed an exclusive licensing agreement with pharmaand GmbH, a global pharmaceutical business based in Vienna, to commercialise rucaparib, an innovative small-molecule oral oncology therapy, across the MENA region. This is in line with our strategy to be a leading provider of oncology medicines in the region. We continue to expect 2025 Branded revenue to grow in the range of 6% to 7% in constant currency, with core EBIT margin close to 25%. Generics In our Generics business we are seeing solid demand across our differentiated portfolio, particularly for our nasal and inhalation products. By focusing on reliability of supply, high service levels and leveraging our US manufacturing facility, we are successfully securing longer-term customer awards. We continue to strengthen our R&D capabilities, including building a team in our new Zagreb, Croatia R&D centre, and are progressing with key development projects that will help strengthen our portfolio and pipeline for the medium to long-term. We are progressing well preparing our Columbus facility to accommodate our recently announced contract manufacturing partnership, and we are seeing increasing demand for our high-quality US-based manufacturing services. We continue to expect Generics revenue to be broadly flat in 2025 with core operating margin of around 16%. International trade policies We are confident that our significant and expanding US manufacturing footprint, which supplies the majority of our US sales, combined with our focus on quality and reliability of supply, positions us well and underpins our resilience in the current environment. We do import some finished products into the US as well as capital equipment, and we have a diversified global supply chain for our raw and packaging materials, including active pharmaceutical ingredients (API). Full year outlook unchanged We continue to expect Group revenue to grow in the range of 4% to 6% and for core operating profit to be in the range of $730 million to $770 million in 2025. Group core operating profit growth, which is around 4% at the midpoint of guidance, will be weighted to the second half. We are monitoring the evolving tariff backdrop and will look to remain agile in responding to both opportunities and impacts where possible, but have not reflected an impact from tariffs in our full year outlook.
Web Release
24-04-2025
- Business
- Web Release
Hikma reiterates full year guidance following good start to the year
Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading ahead of its Annual General Meeting. Riad Mishlawi, Hikma's CEO, said: 'We are pleased to reiterate our Group guidance for 2025. As a global company with strong local expertise and footprint, we are leveraging our manufacturing proficiency and advanced technologies to meet the needs of our customers and patients across our markets. Looking ahead, and recognising the broader geo-political challenges, we are well-positioned. Our step up in R&D investment, alongside local manufacturing enhancements, and strategic partnerships will continue to strengthen our portfolio and pipeline and ensure sustained success.' Injectables Our global Injectables business is delivering a solid revenue performance, driven by each of our three geographies. We are seeing strong demand for our products across our European and MENA markets, where we continue to launch new products. In North America we are benefitting from good demand for the recently launched liraglutide injection and the contribution from the newly acquired Xellia portfolio. This is helping to offset increased competition across some of our existing higher margin products. We expect momentum to improve in the second half driven by new product launches and contract manufacturing. We are making excellent progress in the enhancements to our Bedford, Ohio facility, which will significantly increase our US-based injectables manufacturing capacity. We continue to expect 2025 Injectables revenue to grow in the range of 7% to 9%. Phasing and mix of sales will impact margins in the first half but we continue to expect full year core operating margin to be in the mid-30s. Branded Our Branded business is performing well. We continue to make good progress in building our diversified portfolio of products used to treat chronic illnesses, with a focus on oncology and lifestyle diseases, supported by our global expertise and strong local market position. Our leading presence in the MENA region, combined with the breadth of our reach and strong commercial capabilities positions us as a partner of choice. We recently signed an exclusive licensing agreement with pharmaand GmbH, a global pharmaceutical business based in Vienna, to commercialise rucaparib, an innovative small-molecule oral oncology therapy, across the MENA region. This is in line with our strategy to be a leading provider of oncology medicines in the region. We continue to expect 2025 Branded revenue to grow in the range of 6% to 7% in constant currency, with core EBIT margin close to 25%. Generics In our Generics business we are seeing solid demand across our differentiated portfolio, particularly for our nasal and inhalation products. By focusing on reliability of supply, high service levels and leveraging our US manufacturing facility, we are successfully securing longer-term customer awards. We continue to strengthen our R&D capabilities, including building a team in our new Zagreb, Croatia R&D centre, and are progressing with key development projects that will help strengthen our portfolio and pipeline for the medium to long-term. We are progressing well preparing our Columbus facility to accommodate our recently announced contract manufacturing partnership, and we are seeing increasing demand for our high-quality US-based manufacturing services. We continue to expect Generics revenue to be broadly flat in 2025 with core operating margin of around 16%. International trade policies We are confident that our significant and expanding US manufacturing footprint, which supplies the majority of our US sales, combined with our focus on quality and reliability of supply, positions us well and underpins our resilience in the current environment. We do import some finished products into the US as well as capital equipment, and we have a diversified global supply chain for our raw and packaging materials, including active pharmaceutical ingredients (API). Full year outlook unchanged We continue to expect Group revenue to grow in the range of 4% to 6% and for core operating profit to be in the range of $730 million to $770 million in 2025. Group core operating profit growth, which is around 4% at the midpoint of guidance, will be weighted to the second half. We are monitoring the evolving tariff backdrop and will look to remain agile in responding to both opportunities and impacts where possible, but have not reflected an impact from tariffs in our full year outlook.
Zawya
24-04-2025
- Business
- Zawya
Hikma reiterates full year guidance following good start to the year
Amman, Jordan: Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading ahead of its Annual General Meeting. Riad Mishlawi, Hikma's CEO, said: 'We are pleased to reiterate our Group guidance for 2025. As a global company with strong local expertise and footprint, we are leveraging our manufacturing proficiency and advanced technologies to meet the needs of our customers and patients across our markets. Looking ahead, and recognising the broader geo-political challenges, we are well-positioned. Our step up in R&D investment, alongside local manufacturing enhancements, and strategic partnerships will continue to strengthen our portfolio and pipeline and ensure sustained success." Injectables Our global Injectables business is delivering a solid revenue performance, driven by each of our three geographies. We are seeing strong demand for our products across our European and MENA markets, where we continue to launch new products. In North America we are benefitting from good demand for the recently launched liraglutide injection and the contribution from the newly acquired Xellia portfolio. This is helping to offset increased competition across some of our existing higher margin products. We expect momentum to improve in the second half driven by new product launches and contract manufacturing. We are making excellent progress in the enhancements to our Bedford, Ohio facility, which will significantly increase our US-based injectables manufacturing capacity. We continue to expect 2025 Injectables revenue to grow in the range of 7% to 9%. Phasing and mix of sales will impact margins in the first half but we continue to expect full year core operating margin to be in the mid-30s. Branded Our Branded business is performing well. We continue to make good progress in building our diversified portfolio of products used to treat chronic illnesses, with a focus on oncology and lifestyle diseases, supported by our global expertise and strong local market position. Our leading presence in the MENA region, combined with the breadth of our reach and strong commercial capabilities positions us as a partner of choice. We recently signed an exclusive licensing agreement with pharmaand GmbH, a global pharmaceutical business based in Vienna, to commercialise rucaparib, an innovative small-molecule oral oncology therapy, across the MENA region. This is in line with our strategy to be a leading provider of oncology medicines in the region. We continue to expect 2025 Branded revenue to grow in the range of 6% to 7% in constant currency, with core EBIT margin close to 25%. Generics In our Generics business we are seeing solid demand across our differentiated portfolio, particularly for our nasal and inhalation products. By focusing on reliability of supply, high service levels and leveraging our US manufacturing facility, we are successfully securing longer-term customer awards. We continue to strengthen our R&D capabilities, including building a team in our new Zagreb, Croatia R&D centre, and are progressing with key development projects that will help strengthen our portfolio and pipeline for the medium to long-term. We are progressing well preparing our Columbus facility to accommodate our recently announced contract manufacturing partnership, and we are seeing increasing demand for our high-quality US-based manufacturing services. We continue to expect Generics revenue to be broadly flat in 2025 with core operating margin of around 16%. International trade policies We are confident that our significant and expanding US manufacturing footprint, which supplies the majority of our US sales, combined with our focus on quality and reliability of supply, positions us well and underpins our resilience in the current environment. We do import some finished products into the US as well as capital equipment, and we have a diversified global supply chain for our raw and packaging materials, including active pharmaceutical ingredients (API). Full year outlook unchanged We continue to expect Group revenue to grow in the range of 4% to 6% and for core operating profit to be in the range of $730 million to $770 million in 2025. Group core operating profit growth, which is around 4% at the midpoint of guidance, will be weighted to the second half. We are monitoring the evolving tariff backdrop and will look to remain agile in responding to both opportunities and impacts where possible, but have not reflected an impact from tariffs in our full year outlook. About Hikma Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the MENA and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: *Source: AETOSWire
Zawya
27-02-2025
- Business
- Zawya
Jordan: Hikma Pharmaceuticals reports 'strong' 2024 results with 9% revenue growth
AMMAN: Hikma Pharmaceuticals PLC posted 'robust' financial results for 2024, with revenue climbing 9 per cent to $3.127 billion compared to $2.875 billion in 2023, according to audited figures released on Wednesday. The multinational pharmaceutical company strengthened its market position as the seventh-largest supplier of generic medicines in the US and maintained its standing as the second-largest pharmaceutical company by sales in the MENA region for the second consecutive year, the Jordan News Agency, Petra, reported. Hikma's strategic expansion included the acquisition of Xellia Pharmaceuticals' US finished dosage form business, enhancing its injectables division. The company also secured an agreement to acquire 17 Takeda brands previously licensed to Hikma, a move expected to bolster future profitability in its Branded segment. The company's injectables business, which supplies generic injectable and specialty medicines to hospitals across North America, Europe, and MENA, grew by 9 per cent to $1.306 billion. This growth was attributed to "strong" performance across all three geographical markets and expanded US-based manufacturing capacity through the Xellia acquisition. "In MENA, we saw strong growth across most of our markets, supported by new launches and good demand across our broad portfolio," the company stated. European operations saw 20 per cent growth in proprietary products, benefiting from recent market entries in France, the UK and Spain. The branded business, supplying branded generics and in-licensed patented products across MENA, delivered 8 per cent reported growth by 9 per cent in constant currency to $769 million. Hikma's generics business, which supplies oral, respiratory, and other products to the North American retail market, grew 9 per cent to $1.026 billion, surpassing the $1 billion revenue mark for the first time. The company reported increased market share in sodium oxybate and strong performance from its nasal spray franchise. Hikma CEO Riad Mishlawi expressed confidence in the company's outlook, saying: "It's been another strong year for Hikma with double-digit revenue growth, increased profits and a resilient margin." "We continued to invest in the business to support our future progress with a strategic acquisition alongside new partnerships and agreements," Mishlawi added. © Copyright The Jordan Times. All rights reserved. Provided by SyndiGate Media Inc. (
Jordan Times
26-02-2025
- Business
- Jordan Times
Hikma Pharmaceuticals reports 'strong' 2024 results with 9% revenue growth
Hikma Pharmaceuticals PLC posted 'robust' financial results for 2024, with revenue climbing 9 per cent to $3.127 billion (JT file) AMMAN — Hikma Pharmaceuticals PLC posted 'robust' financial results for 2024, with revenue climbing 9 per cent to $3.127 billion compared to $2.875 billion in 2023, according to audited figures released on Wednesday. The multinational pharmaceutical company strengthened its market position as the seventh-largest supplier of generic medicines in the US and maintained its standing as the second-largest pharmaceutical company by sales in the MENA region for the second consecutive year, the Jordan News Agency, Petra, reported. Hikma's strategic expansion included the acquisition of Xellia Pharmaceuticals' US finished dosage form business, enhancing its injectables division. The company also secured an agreement to acquire 17 Takeda brands previously licensed to Hikma, a move expected to bolster future profitability in its Branded segment. The company's injectables business, which supplies generic injectable and specialty medicines to hospitals across North America, Europe, and MENA, grew by 9 per cent to $1.306 billion. This growth was attributed to "strong" performance across all three geographical markets and expanded US-based manufacturing capacity through the Xellia acquisition. "In MENA, we saw strong growth across most of our markets, supported by new launches and good demand across our broad portfolio," the company stated. European operations saw 20 per cent growth in proprietary products, benefiting from recent market entries in France, the UK and Spain. The branded business, supplying branded generics and in-licensed patented products across MENA, delivered 8 per cent reported growth by 9 per cent in constant currency to $769 million. Hikma's generics business, which supplies oral, respiratory, and other products to the North American retail market, grew 9 per cent to $1.026 billion, surpassing the $1 billion revenue mark for the first time. The company reported increased market share in sodium oxybate and strong performance from its nasal spray franchise. Hikma CEO Riad Mishlawi expressed confidence in the company's outlook, saying: "It's been another strong year for Hikma with double-digit revenue growth, increased profits and a resilient margin." "We continued to invest in the business to support our future progress with a strategic acquisition alongside new partnerships and agreements," Mishlawi added.
